Clinical Trial Update: Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluated the safety and immunogenicity of Tdap vaccination in plasma donors. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Tetanus

Drugs mentioned

• Tdap vaccine (Diphtheria, tetanus, and pertussis vaccine (Tdap))

Snippet

Sponsor: ABO Holdings, Inc. | Conditions: Tetanus, Diphtheria and Acellular Pertussis Vaccination | Phase 2 | Status: COMPLETED